FDA Approves SIGA Technologies’ Intravenous Formulation of TPOXX®
May 19, 2022 By MarketDepth
SIGA Technologies, Inc. (NASDAQ: SIGA) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox.
Shares Gained 18% Premarket
Shares of SIGA Technologies, Inc. (NASDAQ: SIGA) gained over 18% during the premarket trading session following the announcement.
“We are grateful to the FDA for their work leading to approval of IV TPOXX, which will provide access to a broader patient population.”Dr. Dennis Hruby, CSO of SIGA
Currently, the Company’s oral formulation of TPOXX (tecovirimat) is approved in the U.S., Canada and Europe, while its IV formulation was cited in the recent U.S. President’s budget request as being used to treat a patient in the U.S. with monkeypox.
“We are also appreciative to our colleagues at BARDA who have been working with us for many years to include oral and IV TPOXX in U.S. preparedness efforts and look forward to continuing to work with them on our liquid pediatric formulation.”Dr. Dennis Hruby, CSO of SIGA
The IV formulation is meant to offer another option for those who cannot swallow the oral capsules of TPOXX.